Figure 1. Evaluation of disease activity index (DAI) in AD-VEGF-C-treated mice. Mean DAI scores (±SD) were higher in the AD-VEGF-C-treated mice (A) and in recombinant VEGF-C156S-treated mice (B), compared to DSS-treated mice. The difference in DAI scores between AD-VEGF-C-treated mice and DSS-treated mice became significant on the second day of observation and continued to differ thereafter. There was a significant difference in DAI scores between recombinant VEGF-C156S-treated mice and PBS-treated mice on days 3, 5, 6 and 7. *P<0.05 between AD-VEGF-C-treated and DSS-treated mice and between VEGF-C156S-treated mice and PBS-treated mice (n=5/group). ^†P<0.05 compared to water-treated mice (n=5/per group). Statistical analysis was performed by ANOVA and Bonferroni's post-hoc test. AD: adenovirus; PBS: phosphate-buffered saline; AD-VEGF-C: adenovirus vascular endothelial growth factor-C; DSS: dextran sodium sulfate.